Illumina Inc. was ordered to unwind its $7 billion acquisition of cancer startup Grail by the Federal Trade Commission, an uncommon move by antitrust regulators who said the deal raises competition concerns for cancer testing.
To read the entire story, you must be logged in.
Please log in now or register with us.
